Top 3 British Undervalued Stocks With Earnings Growth Up To 20%

The draft UK EU deal to slash post Brexit checks on food exports gives British companies a potential long term boost in trade and profit resilience. That kind of backdrop can make solid, cash generative UK businesses on reasonable valuations even more interesting. This article walks through three financially robust but overlooked stocks that currently screen as both high quality and attractively priced.

The three ideas in this piece are only a starter set, because the full high quality undervalued screen surfaced 10 more businesses with equally compelling narratives that are not covered below. To see the whole field, identify potential breakout candidates, and pressure test your own shortlist, head straight into the High Quality Undervalued Stocks screener

Atalaya Mining Copper (LSE:ATYM)

Atalaya Mining Copper is on this high quality undervalued list because Proyecto Riotinto generates the operating cash that underpins its value metrics, giving investors exposure to copper production backed by tangible assets and a balance sheet that fits the screener brief.

Atalaya Mining Copper operates the Proyecto Riotinto open pit in Spain, producing copper concentrates with silver and gold, and generated about €493 million from mining operations, exploration, development and scrap sales. The group is valued at roughly £1.3b in the market.

"Atalaya Mining Copper is still working toward key milestones on growth projects. The company expects that permitting and the subsequent 18‑month development of Proyecto Touro could add 30,000 tonnes of copper per year at lower cash costs than current operations, which would lift future revenues and support higher net margins once the project is online."

The outcome depends in part on how one cost pressure changes as new production starts to feed through the income statement.

That cost pressure is the fulcrum, and the full narrative for Atalaya Mining Copper shows how cash generation, project timing, and risk factors could be converging into something much more interesting.

AstraZeneca (LSE:AZN)

AstraZeneca is a global prescription medicines group whose oncology blockbusters sit alongside cardiovascular, respiratory, vaccine and rare disease therapies, with oncology cash flows anchoring its place in a high quality undervalued screen. It generated about $62.4b from pharmaceuticals and carries a market value near £215b.

AstraZeneca matters in this list because its cancer franchise already generates substantial cash that can fund the rest of the portfolio. The wider late stage pipeline gives the business multiple opportunities to keep those cash flows resilient for longer.

"The company's robust and diversified late-stage pipeline, particularly in oncology, rare diseases, and cardiovascular or metabolic therapies, is now underpinned by management's disclosure of 12 programs each with risk adjusted peak sales potential above US$5b and several more in the US$3b to US$5b range."

Investors may wish to consider what could happen to future margins and cash generation if a single pressure point in that broad late stage portfolio does not develop as expected.

If that pressure point is what worries you most, the full narrative for AstraZeneca explains where AstraZeneca’s late stage engine could either accelerate or quietly stall next.

Smith & Nephew (LSE:SN.)

Smith & Nephew taps into the high quality undervalued theme through its Orthopaedics arm, where knee and hip implants generate recurring, procedure linked cash flows. Sports Medicine & ENT and Advanced Wound Management round out a broad medical devices portfolio worth about £9.2b in the market.

For an income statement powered by dependable joint replacement hardware and follow on consumables, Smith & Nephew brings a cash rich, balance sheet backed profile that fits this screener’s brief while still leaving room for a potential breakout in investor expectations.

"Growing penetration of CORI handheld robotics, with double digit growth in placements, higher utilization and greater ASC adoption, sets Smith & Nephew up to earn more recurring software, service and implant revenue per site as robotics and enabling technologies become a larger share of global joint replacement and shoulder surgery."

The key swing factor now is how a single pressure point in its largest joint replacement franchise ultimately feeds through to margins and cash generation.

If that pressure point is what you are weighing, the full narrative for Smith & Nephew outlines how robotics momentum, pricing power and mix shifts could be quietly reshaping Smith & Nephew’s earnings profile.

Seeking Alternatives Before Momentum Flies

Fresh ideas move first. By the time every investor spots a breakout, the best entry can be gone. Scan under the radar for now, while it matters, and act while conditions remain favorable.

• Spot under followed opportunities early by tracking 5 high quality undiscovered gems that pair solid fundamentals with stories most investors have not yet caught onto.
• Target resilient income streams with the 5 dividend fortresses and see which high yield payers still look built to handle pressure without blinking.
• Ride long term electrification trends through the 43 power grid technology and infrastructure stocks and focus on businesses connected to grid upgrades before momentum really starts flying.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com